Novel therapy based on camelid nanobodies.

TitleNovel therapy based on camelid nanobodies.
Publication TypeJournal Article
Year of Publication2013
AuthorsUnciti-Broceta, J. Diego, T. Del Castillo, M. Soriano, S. Magez, and J. A. Garcia-Salcedo
JournalTher Deliv
Volume4
Issue10
Pagination1321-36
Date Published2013 Oct
Type of Articlenanobody
ISSN2041-5990
KeywordsAnimals, Antibody Specificity, Camelids, New World, Camels, Chemistry, Pharmaceutical, Drug Carriers, Humans, Immunotherapy, Immunotoxins, Nanomedicine, Protein Conformation, Single-Domain Antibodies, Structure-Activity Relationship
Abstract

Nanobodies (Nbs) are small antibody fragments derived from camelid heavy chain antibodies through recombinant gene technology. Their exceptional physicochemical properties, possibility of humanization and unique antigen recognition properties make them excellent candidates for targeted delivery of biologically active components. Several different therapeutic approaches based on the novel camelid Nbs have been developed to treat a wide range of diseases ranging from immune, bone, blood and neurological disorders; infectious diseases and cancer. This review provides a comprehensive overview of the current state of the use of camelid-derived Nbs as novel therapeutic agents against multiple diseases.

DOI10.4155/tde.13.87
Alternate JournalTher Deliv
PubMed ID24116915
subject_category: 
Research group: